Data has become an indispensable input, throughput, and output for the healthcare industry. In recent years, omics technologies such as genomics and proteomics have generated vast amounts of new data at the cellular level including molecular, structural, and functional levels. Cellular data holds the potential to innovate therapeutics, vaccines, diagnostics, consumer products, or even ancestry services. However, data at the cellular level is generated with rapidly evolving omics technologies. These technologies use scientific knowledge from resource-rich environments. This raises the question of how new ventures can use cellular-level data from omics technologies to create new products and scale their business. We report on a series of interviews and a focus group discussion with entrepreneurs, investors, and data providers. By conceptualizing omics technologies as external enablers, we show how characteristics of cellular-level data negatively affect the combination mechanisms that drive venture creation and growth. We illustrate how data characteristics set boundary conditions for innovation and entrepreneurship and highlight how ventures seek to mitigate their impact.

数据已成为医疗保健行业不可或缺的输入、吞吐量和输出。近年来，基因组学和蛋白质组学等组学技术在细胞水平（包括分子、结构和功能水平）产生了大量新数据。蜂窝数据具有创新疗法、疫苗、诊断、消费产品甚至血统服务的潜力。然而，细胞水平的数据是通过快速发展的组学技术生成的。这些技术利用来自资源丰富环境的科学知识。这就提出了一个问题：新企业如何利用组学技术的细胞级数据来创造新产品并扩大业务规模。我们报道了与企业家、投资者和数据提供商的一系列访谈和焦点小组讨论。通过将组学技术概念化为外部推动因素，我们展示了细胞级数据的特征如何对推动企业创建和增长的组合机制产生负面影响。我们说明了数据特征如何为创新和创业设定边界条件，并强调企业如何寻求减轻其影响。